We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Incyte (INCY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of INCY and the rest of the Medical group's stocks.
Incyte is one of 889 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. INCY is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for INCY's full-year earnings has moved 11.52% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, INCY has gained about 14.86% so far this year. Meanwhile, stocks in the Medical group have lost about 2.46% on average. This means that Incyte is performing better than its sector in terms of year-to-date returns.
Breaking things down more, INCY is a member of the Medical - Biomedical and Genetics industry, which includes 377 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 7.24% so far this year, meaning that INCY is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to INCY as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Incyte (INCY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of INCY and the rest of the Medical group's stocks.
Incyte is one of 889 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. INCY is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for INCY's full-year earnings has moved 11.52% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, INCY has gained about 14.86% so far this year. Meanwhile, stocks in the Medical group have lost about 2.46% on average. This means that Incyte is performing better than its sector in terms of year-to-date returns.
Breaking things down more, INCY is a member of the Medical - Biomedical and Genetics industry, which includes 377 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 7.24% so far this year, meaning that INCY is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to INCY as it looks to continue its solid performance.